Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Part of Amgen, Inc., Amgen Research (Munich) GmbH is a German company located in Munich. The firm produces copper and metal powders. Robert Saller and Peter Kufer are the current co-CEOs of the firm. On June 13, 2002 ECKA Granulate GmbH & Co. KG acquired Amgen Research (Munich) GmbH from Aurubis AG.

Signal Pharmaceuticals is a biopharmaceutical company that was founded by David Anderson (Senior VP & Head of Research), Alan Lewis (CEO), Mark Carmen, and Jackie Johnson and is based in California. It was acquired by Celgene in 2009

SuperGen, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of therapies to treat patients with cancer. Products in Development MP-470—DNA Repair Suppressor: MP-470 is a multi-targeted Tyrosine Kinase Inhibitor that is specific for mutant forms of c-kit, PDGFRa, and FLT3. These protein kinase targets are involved in the growth and proliferation of cancer cells. MP-470 is also a suppressor of Rad51, a DNA repair protein which is involved in resistance to various chemotherapy agents and radiation. SuperGen, Inc. was founded in 1991.

Ohara Pharmaceutical Co., Ltd. manufactures, distributes, imports, and exports pharmaceuticals and related food additives. It also specializes in orphan drugs for Leukemia, Leukocytpenia, stem cell transplantation, and Parkinson's disease. The company was founded on November 5, 1964 and is headquartered in Koka, Japan.

Pierre Fabre Médicament SA manufactures cosmetics and pharmaceutical products. It focuses on research, development, and prescription of medicines and cosmetics. The company was founded on December 31, 1982 and is headquartered in Boulogne-Billancourt, France.

Fresenius Medical Care is a provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1.89 million individuals worldwide. It has a network of 2,716 dialysis clinics in North America, Europe, Latin America, Asia-Pacific, and Africa. It offers specialty pharmacy and laboratory services and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals. The company was founded in 1996 and is headquartered in Bad Homburg, Frankfurt.

Instytut Zootechniki conducts scientific research and development works in the field of animal production.

Viridos develops and commercializes genomic-driven solutions to address global energy and environmental challenges. The company engages in synthesizing and programming DNA in developing and utilizing the technologies in synthetic genomics. It designs and develops microbes for industrial processes and environmental applications. The company also develops microbial cultivation technologies and monitoring approaches that reveal novel microorganisms, suites of new genes, and fermentation platforms for the metabolic engineering of microbes for commercial Bioenergy applications. In addition, it involves in designing advanced biofuels with properties compared to ethanol and biodiesel; harnessing photosynthetic organisms to produce value-added products directly from sunlight and carbon dioxide; developing new biological solutions to enhance production and/or recovery rates of subsurface hydrocarbons; and developing high-yielding, disease resistant, and economic feedstocks. The company's solutions help in improving the production of energy, chemicals, and pharmaceuticals, as well as enabling carbon sequestration and environmental remediation.

Part of GSK Plc, GlaxoSmithKline Intellectual Property Development Ltd. is a British company located in Middlesex that functions as an investment holding company. It was founded in 2012.\nThe company says this about itself: The Company is a member of the GlaxoSmithKline Group (the \"Group\"). The Company's principal activities are the development, enhancement, maintenance, protection and exploitation of intellectual property assets owned by the Company which may include but are not limited to, licensing out intellectual property rights relating to pharmaceutical products to the GlaxoSmithKline Group of companies (the \"Group\") and carrying out research and development activities.

GlaxoSmithKline Intellectual Property (No. 2) Ltd., a subsidiary of GSK Plc, is a company headquartered in Brentford, UK, that provides business support services. The firm was founded in 2012.\nThe company says this about itself: The Company is a member of the GlaxoSmithKline Group (the \"Group\"). The Company's principal activities are the development, enhancement, maintenance, protection and exploitation of intellectual property assets owned by the Company which may include but are not limited to, licensing out intellectual property rights relating to pharmaceutical products to the GlaxoSmithKline Group of companies and carrying out research and development activities.

Epigenomics is a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic tests for cancer. Its cancer diagnostic tests aim at finding cancer at early stages before symptoms occur and are carried out conveniently on body fluids such as blood plasma. These tests potentially address millions of individuals in each of the major markets such as the United States, Europe, and Japan and provide product opportunities each with peak sales potentials of several hundred millions of euros for diagnostics companies worldwide. Its lead test development program is in colorectal cancer. Further test are in development for lung and prostate cancer. Each of its products in development addresses either mass markets or high-value niches. While some of them lend themselves to partnering with established diagnostics industry players, others can be commercialized effectively by Epigenomics itself. The concept of its diagnostic tests in development relies on detecting differences in DNA methylation patterns between healthy and sick individuals or between subgroups of patients for disease classification.

Ceres SAS is a French private company located in Paris with domestic subsidiaries. The firm provides accounting services.

Danone SA engages in the food processing industry. It operates through the following geographical segments: Europe; North America; China, North Asia & Oceania; and Rest of the World. The company was founded on February 2, 1899 and is headquartered in Paris, France.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Metheor Therapeutics Corp is a biotechnology company designing and developing inhibitors of DNA methyltransferase enzymes (DNMTs). Our goal is to produce novel therapeutic compounds that will have a role in the treatment of cancers and other major diseases. While there are two approved DNMT inhibitors being used to treat Myelodysplastic Syndromes (Vidaza and Dacogen), there is a need for new treatments with selective pharmocology and improved toxicity profiles. Our novel approach addresses this need.